{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:13:44Z","timestamp":1787786024312,"version":"build-2784847793"},"reference-count":94,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Therapeutic drug monitoring (TDM) is a well-established tool for guiding psychopharmacotherapy and improving patient care. Despite their established roles in the prescription of psychotropic drugs, the \u201cbehind the curtain\u201d processes of TDM requests are invariably obscure to clinicians, and literature addressing this topic is scarce.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In the present narrative review, we provide a comprehensive overview of the various steps, starting from requesting TDM to interpreting TDM findings, in routine clinical practice. Our goal was to improve clinicians' insights into the numerous factors that may explain the variations in TDM findings due to methodological issues.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We discussed challenges throughout the TDM process, starting from the analyte and its major variation forms, through sampling procedures and pre-analytical conditions, time of blood sampling, sample matrices, and collection tubes, to analytical methods, their advantages and shortcomings, and the applied quality procedures. Additionally, we critically reviewed the current and future advances in the TDM of psychotropic drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The \u201cbehind the curtain\u201d processes enabling TDM involve a multidisciplinary team, which faces numerous challenges in clinical routine. A better understanding of these processes will allow clinicians to join the efforts for achieving higher-quality TDM findings, which will in turn improve treatment effectiveness and safety outcomes of psychotropic agents.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001092","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T04:01:23Z","timestamp":1679371283000},"page":"143-154","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Behind the Curtain: Therapeutic Drug Monitoring of Psychotropic Drugs from a Laboratory Analytical Perspective"],"prefix":"10.1097","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4780-612X","authenticated-orcid":false,"given":"Maike","family":"Scherf-Clavel","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Germany;"},{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) Work Group on \u201cTherapeutic Drug Monitoring\u201d (Chair: Prof. Dr Med. Dipl.-Psych. Stefan Unterecker, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Germany);"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Baumann","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) Work Group on \u201cTherapeutic Drug Monitoring\u201d (Chair: Prof. Dr Med. Dipl.-Psych. Stefan Unterecker, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Germany);"},{"name":"German Society for Clinical Chemistry and Laboratory Medicine e. V. (DGKL), Section Therapeutic Drug Monitoring and Clinical Toxicology, Berlin\/Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenia M.","family":"Hart","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) Work Group on \u201cTherapeutic Drug Monitoring\u201d (Chair: Prof. Dr Med. Dipl.-Psych. Stefan Unterecker, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Germany);"},{"name":"Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Schneider","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) Work Group on \u201cTherapeutic Drug Monitoring\u201d (Chair: Prof. Dr Med. Dipl.-Psych. Stefan Unterecker, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Germany);"},{"name":"Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany;"},{"name":"German Society for Clinical Chemistry and Laboratory Medicine e. V. (DGKL), Section Therapeutic Drug Monitoring and Clinical Toxicology, Berlin\/Bonn;"},{"name":"INSTAND e.V. Society for Promoting Quality Assurance in Medical Laboratories, Duesseldorf, Germany;"},{"name":"German Society for Clinical Chemistry and Laboratory Medicine e. V. (DGKL), Section Therapeutic Drug Monitoring and Clinical Toxicology, Berlin\/Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) Work Group on \u201cTherapeutic Drug Monitoring\u201d (Chair: Prof. Dr Med. Dipl.-Psych. Stefan Unterecker, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Germany);"},{"name":"Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York"},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra, Hempstead, New York"},{"name":"Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Steimer","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) Work Group on \u201cTherapeutic Drug Monitoring\u201d (Chair: Prof. Dr Med. Dipl.-Psych. Stefan Unterecker, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Germany);"},{"name":"Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich, Munich, Germany;"},{"name":"German Society for Clinical Chemistry and Laboratory Medicine e. V. (DGKL), Section Therapeutic Drug Monitoring and Clinical Toxicology, Berlin\/Bonn;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Zernig","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) Work Group on \u201cTherapeutic Drug Monitoring\u201d (Chair: Prof. Dr Med. Dipl.-Psych. Stefan Unterecker, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Germany);"},{"name":"Department of Pharmacology, Medical University of Innsbruck, Innsbruck, Austria;"},{"name":"Private Practice for Psychotherapy and Court-certified Expert Witness, Hall in Tirol, Austria; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Zurek","sequence":"additional","affiliation":[{"name":"Arbeitsgemeinschaft f\u00fcr Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) Work Group on \u201cTherapeutic Drug Monitoring\u201d (Chair: Prof. Dr Med. Dipl.-Psych. Stefan Unterecker, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital of W\u00fcrzburg, Germany);"},{"name":"Medical Laboratory Bremen, Bremen, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/bcp.13047","article-title":"Therapeutic drug monitoring in the era of precision medicine: opportunities!","volume":"82","author":"Cremers","year":"2016","journal-title":"Br J Clin Pharmacol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R4-20250603","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000001118","article-title":"Changes in psychotropic drug blood levels following SARS-CoV-2 vaccination: a two-center cohort study","author":"Kuzin","year":"2023","journal-title":"Ther Drug Monitor"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1515\/cclm-2018-0482","article-title":"Evidence for the positive impact of ISO 9001 and ISO 15189 quality systems on laboratory performance - evaluation of immunohaematology external quality assessment results during 19 years in Austria","volume":"56","author":"Buchta","year":"2018","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"e00062-17","DOI":"10.1128\/CMR.00062-17","article-title":"Practical guidance for clinical microbiology laboratories: implementing a quality management system in the medical microbiology laboratory","volume":"31","author":"Carey","year":"2018","journal-title":"Clin Microbiol Rev."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3343\/alm.2017.37.5.365","article-title":"International organization for standardization (ISO) 15189","volume":"37","author":"Schneider","year":"2017","journal-title":"Ann Lab Med."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-clinpsy-050718-095514","article-title":"History of psychopharmacology","volume":"15","author":"Braslow","year":"2019","journal-title":"Annu Rev Clin Psychol."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.2174\/138161209788168001","article-title":"Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today","volume":"15","author":"L\u00f3pez-Mu\u00f1oz","year":"2009","journal-title":"Curr Pharm Des."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF02244280","article-title":"Treatment of depression with E-10-hydroxynortriptyline - a pilot study on biochemical effects and pharmacokinetics","volume":"103","author":"Nordin","year":"1991","journal-title":"Psychopharmacology"},{"key":"R11-20250603","article-title":"Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with anticonvulsant exposure","author":"Heger","year":"2023","journal-title":"Ther Drug Monitor."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1055\/a-1872-0613","article-title":"Effects of pharmacokinetic gene variation on therapeutic drug levels and antidepressant treatment response","volume":"55","author":"Scherf-Clavel","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.drudis.2011.12.018","article-title":"Compilation of 222 drugs' plasma protein binding data and guidance for study designs","volume":"17","author":"Zhang","year":"2012","journal-title":"Drug Discov Today."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4155\/bio.10.42","article-title":"Bioanalytical method validation: notable points in the 2009 draft EMA Guideline and differences with the 2001 FDA Guidance","volume":"2","author":"Smith","year":"2010","journal-title":"Bioanalysis"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3390\/pharmaceutics13081208","article-title":"The effect of plasma protein binding on the therapeutic monitoring of antiseizure medications","volume":"13","author":"Charlier","year":"2021","journal-title":"Pharmaceutics"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","article-title":"The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery","volume":"9","author":"Smith","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00007691-200502000-00014","article-title":"The pH dependency of the binding of drugs to plasma proteins in man","volume":"27","author":"Hinderling","year":"2005","journal-title":"Ther Drug Monit."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","article-title":"Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance","volume":"75","author":"Marzolini","year":"2004","journal-title":"Clin Pharmacol Ther."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/ph14060514","article-title":"Therapeutic drug monitoring of second- and third-generation antipsychotic drugs-influence of smoking behavior and inflammation on pharmacokinetics","volume":"14","author":"Moschny","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"733935","DOI":"10.3389\/fphar.2021.733935","article-title":"Influence of inflammation on cytochromes P450 activity in adults: a systematic review of the literature","volume":"12","author":"Lenoir","year":"2021","journal-title":"Front Pharmacol."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2017.03.045","article-title":"Elevated clozapine levels associated with infection: a systematic review","volume":"192","author":"Clark","year":"2018","journal-title":"Schizophrenia Res."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/0091217417749799","article-title":"Two cases of high serum clozapine concentrations occurring during inflammation in Chinese patients","volume":"53","author":"Ruan","year":"2018","journal-title":"Int J Psychiatry Med."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"85","DOI":"10.59566\/IJBS.2006.2085","article-title":"Chiral drugs: an overview","volume":"2","author":"Nguyen","year":"2006","journal-title":"Int J Biomed Sci."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0924-977X(02)00051-2","article-title":"Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram","volume":"12","author":"Baumann","year":"2002","journal-title":"Eur Neuropsychopharmacol."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/BF00314865","article-title":"Stereoselective pharmacokinetics of doxepin isomers","volume":"42","author":"Midha","year":"1992","journal-title":"Eur J Clin Pharmacol."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00213-012-2699-8","article-title":"Flupentixol: relevance of stereoselective therapeutic drug monitoring","volume":"221","author":"Baumann","year":"2012","journal-title":"Psychopharmacology (Berl)."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-3252-8_1","article-title":"Mass spectrometry in clinical laboratory: applications in therapeutic drug monitoring and toxicology","volume":"1383","author":"Garg","year":"2016","journal-title":"Methods Mol Biol."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clinbiochem.2020.03.004","article-title":"After another decade: LC-MS\/MS became routine in clinical diagnostics","volume":"82","author":"Seger","year":"2020","journal-title":"Clin Biochem."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.3390\/molecules25174026","article-title":"Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM)","volume":"25","author":"Tuzimski","year":"2020","journal-title":"Molecules"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"e995","DOI":"10.4088\/JCP.15f10219","article-title":"Sustained-release, extended-release, and other time-release formulations in neuropsychiatry","volume":"76","author":"Andrade","year":"2015","journal-title":"J Clin Psychiatry."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/17425247.2020.1788541","article-title":"Release mechanisms and applications of drug delivery systems for extended-release","volume":"17","author":"Wang","year":"2020","journal-title":"Expert Opin Drug Deliv."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1586\/ern.12.138","article-title":"The pharmacology and formulation of paliperidone extended release","volume":"12","author":"Chue","year":"2012","journal-title":"Expert Rev Neurother."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pnpbp.2008.09.026","article-title":"Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release","volume":"33","author":"Figueroa","year":"2009","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00004850-199703000-00002","article-title":"Long-term treatment of depression: is there a use for depot antidepressants?","volume":"12","author":"Baumann","year":"1997","journal-title":"Int Clin Psychopharmacol."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/FTD.0000000000000830","article-title":"Therapeutic drug monitoring of long-acting injectable antipsychotic drugs","volume":"43","author":"Schoretsanitis","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","article-title":"Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview","volume":"35","author":"Correll","year":"2021","journal-title":"CNS Drugs"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/pharmaceutics13070935","article-title":"Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics","volume":"13","author":"Toja-Camba","year":"2021","journal-title":"Pharmaceutics"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/15622975.2021.1878427","article-title":"Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants","volume":"22","author":"Eap","year":"2021","journal-title":"World J Biol Psychiatry."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"19cs13169","DOI":"10.4088\/JCP.19cs13169","article-title":"Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: a Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft Fur Neuropsychopharmakologie und Pharmakopsychiatrie","volume":"81","author":"Schoretsanitis","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"R43-20250603","first-page":"17","article-title":"Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents","volume":"9","author":"Sheehan","year":"2012","journal-title":"Innov Clin Neurosci."},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/0269881109106914","article-title":"A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia","volume":"24","author":"Berwaerts","year":"2010","journal-title":"J Psychopharmacol."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/10408363.2018.1499708","article-title":"Sample management for clinical biochemistry assays: are serum and plasma interchangeable specimens?","volume":"55","author":"Lima-Oliveira","year":"2018","journal-title":"Crit Rev Clin Lab Sci."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/ajcp\/62.4.545","article-title":"Serum versus heparinized plasma for eighteen common chemistry tests: is serum the appropriate specimen?","volume":"62","author":"Ladenson","year":"1974","journal-title":"Am J Clin Pathol."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ajcp\/61.1.108","article-title":"A comparison of serum versus heparinized plasma for routine chemistry tests","volume":"61","author":"Lum","year":"1974","journal-title":"Am J Clin Pathol."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/clinchem\/35.1.151","article-title":"Differences between values for plasma and serum in tests performed in the Ektachem 700 XR Analyzer, and evaluation of \"plasma separator tubes (PST)","volume":"35","author":"Doumas","year":"1989","journal-title":"Clin Chem."},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/FTD.0000000000000478","article-title":"Clozapine and norclozapine concentrations in paired human plasma and serum samples","volume":"40","author":"Handley","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF01956868","article-title":"Plasma or serum in therapeutic drug monitoring and clinical toxicology","volume":"10","author":"Uges","year":"1988","journal-title":"Pharmaceutisch Weekbl Sci."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0269881121991567","article-title":"Point-of-care measurement of clozapine concentration using a finger-stick blood sample","volume":"35","author":"Taylor","year":"2021","journal-title":"J Psychopharmacol."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2125.2003.01821.x","article-title":"Comparability of whole-blood and plasma clozapine and norclozapine concentrations","volume":"56","author":"Flanagan","year":"2003","journal-title":"Br J Clin Pharmacol."},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0022-3956(73)90005-8","article-title":"Intracellular lithium concentration and clinical response: towards a membrane theory of depression","volume":"10","author":"Mendels","year":"1973","journal-title":"J Psychiatr Res."},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"113102","DOI":"10.1016\/j.jpba.2020.113102","article-title":"Opportunities and obstacles for microsampling techniques in bioanalysis: special focus on DBS and VAMS","volume":"182","author":"Londhe","year":"2020","journal-title":"J Pharm Biomed Anal."},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jpba.2018.12.040","article-title":"LC-MS application for therapeutic drug monitoring in alternative matrices","volume":"166","author":"Avataneo","year":"2019","journal-title":"J Pharm Biomed Anal."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/mas.21441","article-title":"The use of mass spectrometry to analyze dried blood spots","volume":"35","author":"Wagner","year":"2016","journal-title":"Mass Spectrom Rev."},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FTD.0000000000000643","article-title":"Official international association for therapeutic drug monitoring and clinical toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring","volume":"41","author":"Capiau","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1515\/cclm-2013-0228","article-title":"Current and future use of \"dried blood spot\" analyses in clinical chemistry","volume":"51","author":"Lehmann","year":"2013","journal-title":"Clin Chem Lab Med (CCLM)."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.euroneuro.2017.01.009","article-title":"Dried Blood Spot sampling in psychiatry: perspectives for improving therapeutic drug monitoring","volume":"27","author":"Martial","year":"2017","journal-title":"Eur Neuropsychopharmacol."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1515\/cclm-2019-0784","article-title":"Therapeutic drug monitoring of anti-epileptic drugs - a clinical verification of volumetric absorptive micro sampling","volume":"58","author":"Canisius","year":"2020","journal-title":"Clin Chem Lab Med (CCLM)."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bcpt.13269","article-title":"Development and clinical applications of the dried blood spot method for therapeutic drug monitoring of anti-epileptic drugs","volume":"125","author":"Min","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/FTD.0000000000000777","article-title":"Comparison of novel immunoassay with liquid chromatography\/tandem mass spectrometry (LC-MS\/MS) for therapeutic drug monitoring of clozapine","volume":"42","author":"Buckley","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1515\/CCLM.2004.013","article-title":"Evaluation of a new generation of plastic evacuated blood-collection tubes in clinical chemistry, therapeutic drug monitoring, hormone and trace metal analysis","volume":"42","author":"Boeynaems","year":"2004","journal-title":"Clin Chem Lab Med (CCLM)."},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1515\/CCLM.2000.045","article-title":"Suitability of collection tubes with separator gels for collecting and storing blood samples for therapeutic drug monitoring (TDM)","volume":"38","author":"Karppi","year":"2000","journal-title":"Clin Chem Lab Med."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00007691-198412000-00011","article-title":"Blood collection tubes for tricyclic antidepressant drugs: a reevaluation","volume":"6","author":"Orsulak","year":"1984","journal-title":"Ther Drug Monit."},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00007691-200008000-00011","article-title":"Time-dependent absorption of therapeutic drugs by the gel of the Greiner Vacuette blood collection tube","volume":"22","author":"Dasgupta","year":"2000","journal-title":"Ther Drug Monit."},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cca.2018.10.043","article-title":"The right blood collection tube for therapeutic drug monitoring and toxicology screening procedures: standard tubes, gel or mechanical separator?","volume":"488","author":"Schrapp","year":"2019","journal-title":"Clinica Chim Acta."},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/ajcp\/101.4.456","article-title":"Absorption of therapeutic drugs by barrier gels in serum separator blood collection tubes: volume- and time-dependent Reduction in Total and free drug concentrationsa","volume":"101","author":"Dasgupta","year":"1994","journal-title":"Am J Clin Pathol."},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00007691-199005000-00011","article-title":"Suitability of collection tubes with separator gels for therapeutic drug monitoring","volume":"12","author":"Koch","year":"1990","journal-title":"Ther Drug Monit."},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00007691-200106000-00013","article-title":"Stability of therapeutic drugs in serum collected in vacutainer serum separator tubes containing a new gel (SST II)","volume":"23","author":"Bush","year":"2001","journal-title":"Ther Drug Monit."},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/FTD.0000000000000592","article-title":"Substantial differences in serum concentrations of psychoactive drugs measured in samples stored for 2 Days or more on standard serum tubes versus serum tubes containing gel separators","volume":"41","author":"Wollmann","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4155\/bio.09.20","article-title":"Factors affecting the stability of drugs and drug metabolites in biological matrices","volume":"1","author":"Briscoe","year":"2009","journal-title":"Bioanalysis"},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00007691-200408000-00019","article-title":"Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service","volume":"26","author":"Heller","year":"2004","journal-title":"Ther Drug Monit."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1373\/clinchem.2007.088344","article-title":"Errors in a stat laboratory: types and frequencies 10 years later","volume":"53","author":"Carraro","year":"2007","journal-title":"Clin Chem."},{"key":"R76-20250603","first-page":"020705","article-title":"European survey on preanalytical sample handling - Part 2: practices of European laboratories on monitoring and processing haemolytic, icteric and lipemic samples. On behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)","volume":"29","author":"Cadamuro","year":"2019","journal-title":"Biochem Med (Zagreb)."},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"248","DOI":"10.11613\/BM.2014.027","article-title":"Pre-analytical errors management in the clinical laboratory: a five-year study","volume":"24","author":"Gimenez-Marin","year":"2014","journal-title":"Biochem Med (Zagreb)."},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/10408363.2011.600228","article-title":"Hemolyzed specimens: a major challenge for emergency departments and clinical laboratories","volume":"48","author":"Lippi","year":"2011","journal-title":"Crit Rev Clin Lab Sci."},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/FTD.0000000000000901","article-title":"Review of the preanalytical errors that impact therapeutic drug monitoring","volume":"43","author":"Peck Palmer","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.3390\/molecules25215083","article-title":"New methods used in pharmacokinetics and therapeutic monitoring of the first and newer generations of antiepileptic drugs (AEDs)","volume":"25","author":"Sommerfeld-Klatta","year":"2020","journal-title":"Molecules"},{"issue":"suppl 1","key":"R81-20250603","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev."},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/5807218","article-title":"Determination of chlorpromazine, haloperidol, levomepromazine, olanzapine, risperidone, and sulpiride in human plasma by liquid chromatography\/tandem mass spectrometry (LC-MS\/MS)","volume":"2018","author":"Khelfi","year":"2018","journal-title":"Int J Anal Chem."},{"key":"R83-20250603","first-page":"143","article-title":"Clinical chemistry laboratory automation in the 21st century - amat victoria curam (victory loves careful preparation)","volume":"35","author":"Armbruster","year":"2014","journal-title":"Clin Biochem Rev."},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11418-017-1144-z","article-title":"Enzyme-linked immunosorbent assay for the quantitative\/qualitative analysis of plant secondary metabolites","volume":"72","author":"Sakamoto","year":"2018","journal-title":"J Nat Med."},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.forsciint.2005.03.022","article-title":"Drug screening and confirmation by GC-MS: comparison of EMIT II and Online KIMS against 10 drugs between US and England laboratories","volume":"157","author":"Lu","year":"2006","journal-title":"Forensic Sci Int."},{"key":"R88-20250603","first-page":"1","article-title":"Monoplex and multiplex immunoassays: approval, advancements, and alternatives","author":"Ahsan","year":"2021","journal-title":"Comp Clin Path."},{"key":"R90-20250603","first-page":"19","article-title":"Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry","volume":"30","author":"Pitt","year":"2009","journal-title":"Clin Biochem Rev."},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3343\/alm.2022.42.2.121","article-title":"Review of the use of liquid chromatography-tandem mass spectrometry in clinical laboratories: Part I-development","volume":"42","author":"Rappold","year":"2022","journal-title":"Ann Lab Med."},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"e4788","DOI":"10.1002\/jms.4788","article-title":"Utility, promise, and limitations of liquid chromatography-mass spectrometry-based therapeutic drug monitoring in precision medicine","volume":"56","author":"Gaspar","year":"2021","journal-title":"J Mass Spectrom."},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/0004563214557678","article-title":"Liquid chromatography tandem mass spectrometry in the clinical laboratory","volume":"52","author":"Adaway","year":"2015","journal-title":"Ann Clin Biochem."},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.clinbiochem.2016.05.001","article-title":"LC-MS\/MS as a tool for TDM services: where are we?","volume":"49","author":"Shipkova","year":"2016","journal-title":"Clin Biochem."},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jchromb.2006.02.042","article-title":"High throughput therapeutic drug monitoring of clozapine and metabolites in serum by on-line coupling of solid phase extraction with liquid chromatography-mass spectrometry","volume":"834","author":"Niederl\u00e4nder","year":"2006","journal-title":"J Chromatogr B."},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.clinbiochem.2008.02.017","article-title":"A decade of HPLC-MS\/MS in the routine clinical laboratory--goals for further developments","volume":"41","author":"Vogeser","year":"2008","journal-title":"Clin Biochem."},{"key":"R98-20250603","first-page":"8","article-title":"Modular analytics: a new approach to automation in the clinical laboratory","volume":"2005","author":"Horowitz","year":"2005","journal-title":"J Automated Methods Manag Chem."},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1515\/cclm-2014-1149","article-title":"How to define a significant deviation from the expected internal quality control result","volume":"53","author":"Ceriotti","year":"2015","journal-title":"Clin Chem Lab Med (CCLM)."},{"key":"R100-20250603","article-title":"Richtlinie der Bundes\u00e4rztekammer zur Qualit\u00e4tssicherung laboratoriumsmedizinischer Untersuchungen","year":"2019","journal-title":"Deutsches \u00c4rzteblatt."},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00769-007-0269-2","article-title":"Internal quality control and ISO 15189","volume":"12","author":"Fuentes-Arderiu","year":"2007","journal-title":"Accreditation Qual Assur."},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1515\/cclm-2017-1179","article-title":"External quality assessment programs in the context of ISO 15189 accreditation","volume":"56","author":"Sciacovelli","year":"2018","journal-title":"Clin Chem Lab Med (CCLM)."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:05:40Z","timestamp":1748970340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001092","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}